Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-17 15:31 | 2025-11-13 | BHVN | Biohaven Ltd. | Bailey Gregory | Director | BUY | $7.50 | 400,000 | $3,000,000 | 2,020,071 |
| 2025-11-18 00:16 | 2025-11-13 | AMPH | Amphastar Pharmaceuticals Inc. | Petersen Floyd F. | Director | OPT+S | $26.49 | 16,679 | $441,837 | 75,531 |
| 2025-11-18 00:59 | 2025-11-13 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $5.25 | 276,179 | $1,449,940 | 276,179 |
| 2025-11-18 00:12 | 2025-11-13 | VRTX | VERTEX PHARMACEUTICALS INC / MA | LEIDEN JEFFREY M | Director, Officer | OPT+S | $440.60 | 73,292 | $32,292,323 | 24,026 |
| 2025-11-18 03:23 | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.96 | 134,553 | $128,781 | 3,515,880 |
| 2025-11-18 03:20 | 2025-11-13 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $0.96 | 209,652 | $200,658 | 5,481,539 |
| 2025-11-17 17:02 | 2025-11-13 | CRVO | CervoMed Inc. | Gregoire Sylvie | Director, 10% owner | BUY | $7.53 | 7,847 | $59,101 | 1,693 |
| 2025-11-17 17:01 | 2025-11-13 | CRVO | CervoMed Inc. | ALAM JOHN J | Director, Officer, 10% owner | BUY | $7.53 | 7,847 | $59,101 | 1,707 |
| 2025-11-17 17:01 | 2025-11-14 | CRVO | CervoMed Inc. | Winton Matthew | Officer | BUY | $7.57 | 10,000 | $75,700 | 10,000 |
| 2025-11-17 15:30 | 2025-11-13 | BHVN | Biohaven Ltd. | CHILDS JOHN W | Director | BUY | $7.50 | 3,333,333 | $24,999,998 | 5,653,904 |
| 2025-11-18 02:01 | 2025-11-13 | ANIP | Ani Pharmaceuticals Inc. | Walsh Patrick D | Director | SELL | $86.88 | 8,643 | $750,904 | 61,405 |
| 2025-11-15 00:00 | 2025-11-13 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,030.26 | 46,606 | $48,016,097 | 93,060,372 |
| 2025-11-15 04:00 | 2025-11-14 | MNKD | MANNKIND CORP | Singh Sanjay R | Officer | SELL | $5.03 | 18,777 | $94,448 | 455,211 |
| 2025-11-15 04:00 | 2025-11-14 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Officer | OPT+S | $30.00 | 3,333 | $99,990 | 84,974 |
| 2025-11-15 00:50 | 2025-11-12 | BBIO | BridgeBio Pharma, Inc. | Valantine Hannah | Director | OPT+S | $66.07 | 25,484 | $1,683,728 | 7,465 |
| 2025-11-15 00:35 | 2025-11-12 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $40.94 | 19,900 | $814,706 | 31,086 |
| 2025-11-15 01:13 | 2025-11-12 | AMRX | Amneal Pharmaceuticals Inc. | Shah Nikita | Officer | OPT+S | $11.92 | 131,856 | $1,571,724 | 146,403 |
| 2025-11-15 05:00 | 2025-11-13 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Randhawa Simrat | Officer | OPT+S | $37.55 | 196,538 | $7,379,884 | 4,000 |
| 2025-11-14 16:17 | 2025-11-13 | ZOMDF | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.10 | 150,000 | $14,550 | 5,784,101 |
| 2025-11-15 02:42 | 2025-11-12 | SPRY | ARS Pharmaceuticals, Inc. | Chakma Justin | Officer | OPT+S | $8.87 | 166,380 | $1,476,140 | 0 |
| 2025-11-15 01:28 | 2025-11-12 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | OPT+S | $349.17 | 996 | $347,770 | 0 |
| 2025-11-15 01:35 | 2025-11-12 | ONC | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $365.22 | 16,009 | $5,846,820 | 0 |
| 2025-11-15 05:00 | 2025-11-13 | WVE | Wave Life Sciences Ltd. | Rawcliffe Adrian | Director | SELL | $6.79 | 16,115 | $109,421 | 12,700 |
| 2025-11-14 18:45 | 2025-11-12 | PRGO | PERRIGO Co plc | Parker Geoffrey M. | Director | BUY | $14.18 | 7,500 | $106,350 | 17,375 |
| 2025-11-15 00:04 | 2025-11-12 | AGIO | Agios Pharmaceuticals Inc. | Scadden David | Director | OPT+S | $43.84 | 200 | $8,768 | 17,603 |
| 2025-11-15 04:00 | 2025-11-14 | KURA | Kura Oncology, Inc. | Bair Teresa Brophy | Officer | SELL | $11.18 | 8,804 | $98,401 | 188,139 |
| 2025-11-15 04:00 | 2025-11-14 | KURA | Kura Oncology, Inc. | Powl Brian T. | Officer | SELL | $11.18 | 8,887 | $99,329 | 139,689 |
| 2025-11-15 04:00 | 2025-11-14 | KURA | Kura Oncology, Inc. | Leoni Mollie | Officer | SELL | $11.18 | 15,485 | $173,074 | 225,454 |
| 2025-11-15 04:00 | 2025-11-14 | KURA | Kura Oncology, Inc. | DOYLE THOMAS JAMES | Officer | SELL | $11.18 | 4,539 | $50,732 | 130,257 |
| 2025-11-15 04:00 | 2025-11-14 | KURA | Kura Oncology, Inc. | FORD KATHLEEN | Officer | SELL | $11.18 | 6,902 | $77,143 | 105,373 |
| 2025-11-14 16:00 | 2025-11-12 | CATX | Perspective Therapeutics, Inc. | Williamson Robert F III | Director | BUY | $2.10 | 9,498 | $19,946 | 9,864 |
| 2025-11-15 02:43 | 2025-11-13 | SPRY | ARS Pharmaceuticals, Inc. | Dorsey Brian | Officer | OPT+S | $8.71 | 21,828 | $190,050 | 10,789 |
| 2025-11-15 01:00 | 2025-11-12 | CPRX | CATALYST PHARMACEUTICALS, INC. | Elsbernd Brian | Officer | SELL | $22.70 | 40,000 | $908,000 | 231,039 |
| 2025-11-15 00:30 | 2025-11-13 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Director | SELL | $4.74 | 15,000 | $71,168 | 62,252 |
| 2025-11-15 02:14 | 2025-11-13 | WVE | Wave Life Sciences Ltd. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | BUY | $6.69 | 1,000 | $6,688 | 18,203,009 |
| 2025-11-15 00:10 | 2025-11-12 | COLL | COLLEGIUM PHARMACEUTICAL, INC | Fallon John A. | Director | OPT+S | $47.21 | 34,853 | $1,645,536 | 64,634 |
| 2025-11-14 14:00 | 2025-11-11 | TBPH | Theravance Biopharma, Inc. | BROSHY ERAN | Director | OPT+S | $17.98 | 45,000 | $809,249 | 60,204 |
| 2025-11-15 00:13 | 2025-11-12 | ALNY | Alnylam Pharmaceuticals Inc. | Greenstreet Yvonne | Director, Officer | OPT+S | $452.75 | 25,650 | $11,613,004 | 65,409 |
| 2025-11-15 01:12 | 2025-11-13 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Levy Richard S | Director | OPT+S | $520.96 | 8,500 | $4,428,197 | 21,197 |
| 2025-11-15 00:02 | 2025-11-13 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer | OPT+S | $5.47 | 121,117 | $662,510 | 4,479 |
| 2025-11-15 00:12 | 2025-11-12 | INSM | INSMED Inc | Schaeffer Orlov S Nicole | Officer | OPT+S | $194.00 | 30,000 | $5,820,060 | 36,461 |
| 2025-11-15 01:20 | 2025-11-12 | PTCT | PTC THERAPEUTICS, INC. | Reeve Emma | Director | OPT+S | $74.50 | 7,333 | $546,309 | 6,666 |
| 2025-11-15 00:26 | 2025-11-13 | ANIP | Ani Pharmaceuticals Inc. | Cook Meredith | Officer | SELL | $87.27 | 400 | $34,908 | 75,274 |
| 2025-11-15 00:30 | 2025-11-12 | ANIP | Ani Pharmaceuticals Inc. | Gassert Chad | Officer | SELL | $89.06 | 14,736 | $1,312,435 | 158,490 |
| 2025-11-14 00:00 | 2025-11-12 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,011.18 | 305,000 | $308,411,212 | 93,106,978 |
| 2025-11-14 04:13 | 2025-11-10 | SEPN | Septerna, Inc. | Long Daniel D. | Officer | SELL | $18.06 | 3,501 | $63,223 | 92,911 |
| 2025-11-14 03:01 | 2025-11-11 | MLYS | Mineralys Therapeutics, Inc. | Gold Alexander M | Director | OPT+S | $45.45 | 34,675 | $1,576,093 | 0 |
| 2025-11-14 01:02 | 2025-11-12 | CNTA | Centessa Pharmaceuticals plc | Bush Tia L | Officer | OPT+S | $26.00 | 40,000 | $1,040,000 | 121,503 |
| 2025-11-14 04:57 | 2025-11-11 | VERA | Vera Therapeutics, Inc. | Young Joseph R | Officer | OPT+S | $29.06 | 15,000 | $435,875 | 47,839 |
| 2025-11-14 03:01 | 2025-11-13 | MLYS | Mineralys Therapeutics, Inc. | Karydas Daphne | Director | OPT+S | $45.99 | 15,000 | $689,798 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.